NO20061909L - 3-(4-aminofenyl)tienopyrimid-4-on derivater som MCH R-antagonister for behandling av fedme, diabetes,depresjon og angst - Google Patents

3-(4-aminofenyl)tienopyrimid-4-on derivater som MCH R-antagonister for behandling av fedme, diabetes,depresjon og angst

Info

Publication number
NO20061909L
NO20061909L NO20061909A NO20061909A NO20061909L NO 20061909 L NO20061909 L NO 20061909L NO 20061909 A NO20061909 A NO 20061909A NO 20061909 A NO20061909 A NO 20061909A NO 20061909 L NO20061909 L NO 20061909L
Authority
NO
Norway
Prior art keywords
mch
anxiety
obesity
antagonists
diabetes
Prior art date
Application number
NO20061909A
Other languages
English (en)
Norwegian (no)
Inventor
Anthony Louis Handlon
Donald L Hertzog
Clifton L Hyman
Kevin K Barvian
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20061909L publication Critical patent/NO20061909L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20061909A 2003-10-23 2006-04-28 3-(4-aminofenyl)tienopyrimid-4-on derivater som MCH R-antagonister for behandling av fedme, diabetes,depresjon og angst NO20061909L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51380003P 2003-10-23 2003-10-23
PCT/US2004/034846 WO2005042541A1 (fr) 2003-10-23 2004-10-21 Derives de 3-(4-aminophenyl)-thienopyrimid-4-one utilises comme antagonistes de mch r1 pour le traitement de l'obesite, du diabete, de la depression et de l'anxiete

Publications (1)

Publication Number Publication Date
NO20061909L true NO20061909L (no) 2006-05-03

Family

ID=34549304

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061909A NO20061909L (no) 2003-10-23 2006-04-28 3-(4-aminofenyl)tienopyrimid-4-on derivater som MCH R-antagonister for behandling av fedme, diabetes,depresjon og angst

Country Status (15)

Country Link
US (1) US20070078125A1 (fr)
EP (1) EP1678184A1 (fr)
JP (1) JP2007509158A (fr)
KR (1) KR20060100412A (fr)
CN (1) CN1871242A (fr)
AU (1) AU2004285913A1 (fr)
BR (1) BRPI0415667A (fr)
CA (1) CA2543122A1 (fr)
CO (1) CO5690599A2 (fr)
IL (1) IL174693A0 (fr)
MA (1) MA28111A1 (fr)
MX (1) MXPA06003997A (fr)
NO (1) NO20061909L (fr)
WO (1) WO2005042541A1 (fr)
ZA (1) ZA200603181B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011284A1 (fr) * 2005-07-15 2007-01-25 Astrazeneca Ab Agents thérapeutiques
WO2007039462A2 (fr) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Derives d'indane utilises comme antagonistes du recepteur mch
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
CA2626220A1 (fr) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Nouveaux derives de pyrazinone substituee a utiliser lors de maladies mediees par mch-1
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
TW200800908A (en) * 2006-02-15 2008-01-01 Sanofi Aventis Novel azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
TW200800907A (en) 2006-02-15 2008-01-01 Sanofi Aventis Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
CN101370501A (zh) * 2006-02-15 2009-02-18 塞诺菲-安万特股份有限公司 新的氮杂环基取代的芳基噻吩并嘧啶酮类、其制备方法以及其作为药物的用途
WO2007093365A2 (fr) * 2006-02-15 2007-08-23 Sanofi-Aventis Nouvelles arylthiénopyrimidinones à substitution aminoalcool, leur procédé de préparation et leur utilisation comme médicaments
JP5198439B2 (ja) * 2006-06-08 2013-05-15 イーライ リリー アンド カンパニー 新規なmch受容体アンタゴニスト
WO2008020799A1 (fr) * 2006-08-18 2008-02-21 Astrazeneca Ab Dérivés de thiénopyrimidin-4-one et de thiénopyridazin-7-one en tant qu'antagonistes du mch rl
CA2673654A1 (fr) 2007-01-10 2008-07-17 Albany Molecular Research, Inc. Indazoles 5-pyridinone substituees
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
CA2693377A1 (fr) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. Indazoles substitues par du 5-pyridinone
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2406233B1 (fr) * 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Analogues d'aza-pyridone utiles en tant que antagonistes des récepteurs de l'hormone concentrant la mélanine
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
KR20130013199A (ko) * 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
ES2673183T3 (es) 2011-08-26 2018-06-20 On Light Sciences, Inc. Sistema y método de retirada de tatuajes
JP2023509800A (ja) * 2020-01-10 2023-03-09 コンシナンス セラピューティクス, インコーポレイテッド 薬物の治療的組み合わせ及びそれらの使用方法
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
IL174693A0 (en) 2006-08-20
CO5690599A2 (es) 2006-10-31
CN1871242A (zh) 2006-11-29
MXPA06003997A (es) 2006-07-05
MA28111A1 (fr) 2006-08-01
KR20060100412A (ko) 2006-09-20
WO2005042541A1 (fr) 2005-05-12
JP2007509158A (ja) 2007-04-12
BRPI0415667A (pt) 2006-12-19
CA2543122A1 (fr) 2005-05-12
AU2004285913A1 (en) 2005-05-12
US20070078125A1 (en) 2007-04-05
EP1678184A1 (fr) 2006-07-12
ZA200603181B (en) 2008-01-30

Similar Documents

Publication Publication Date Title
NO20061909L (no) 3-(4-aminofenyl)tienopyrimid-4-on derivater som MCH R-antagonister for behandling av fedme, diabetes,depresjon og angst
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
NO20050068L (no) Nye karboksamid-forbindelser med en mch-antagonist-virkning, medikamenter inneholdende disse forbindelsene, og fremgangsmater for fremstilling derav
NO20092342L (no) Azaspiroderivativater
NO20092762L (no) 2-aza-bicyklo[3.1.0]heksanderivater
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
HK1092152A1 (en) Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
NO20091766L (no) Spiro-piperidinderivater
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20083500L (no) 1,4-disubstituerte 3-cyano-pyridonderivater og deres anvendelse som positiv-allosteriske modulatorer av mGluR2 receptorer
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
WO2003028641A3 (fr) Antagonistes du recepteur de la mch
NO20050749L (no) Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20050745L (no) Nye amidforbindelser med MCH-antagonistisk effekt, og medikamenter inneholdende slike forbindelser
GEP20074197B (en) 5ht2c receptor modulators
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
CY1111603T1 (el) Παραγωγα benzimidazole και η χρηση τους για την τροποποιηση της συνθεσης ληπτη gabaa
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
NO20081014L (no) Sammensetninger
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application